 SAN FRANCISCO, Nov. 22, 2021 GLOBE NEWSWIRE -- Olema Pharmaceuticals, Inc. Olema or Olema Oncology, Nasdaq: OLMA, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for womens cancers, today announced two poster presentations on OP-1250, an investigational complete estrogen receptor ER antagonist CERAN and a selective ER degrader SERD in development for the treatment of metastatic breast cancer and other womens cancers, at the upcoming San Antonio Breast Cancer Symposium SABCS meeting being held December 7-10, 2021, at the Henry B. Gonzalez Convention Center in San Antonio, Texas. 